Alzheimer's Disease and Dementia References
- Alvarez XA, Cacabelos R, Sampedro C, et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol. 2010;18(1):59-68. doi: 10.1111/j.1468-1331.2010.03092.x. Accessed 15 Mar 2011. PMID: 20500802
- American Psychiatric Association. Practice guidelines for the treatment of patients with Alzheimer’s disease and other dementias of late life. Am J Psychiatry. 1997 May;154(Suppl 5):001-39. PMID: 9140238
- Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007 Jul;69(5):459-469. PMID: 17664405
- Bain LJ. A review of the "State of the Art" on mild cognitive impairment: the fourth annual symposium. Alzheimers Dement. 2006 Jul;2(3):246-256. PMID: 19595894
- Corey-Bloom J. Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int J Clin Pract. 2003 Apr;57(3):219-223. PMID: 12723727
- Delagarza VW. Pharmacologic treatment of Alzheimer's disease: an update. Am Fam Physician. 2003 Oct;68(7):1365-1372. PMID: 14567491
- Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry. 2003 Mar;11(2):131-145. PMID: 12611743
- Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May;56(9):1154-1166. PMID: 11342679
- Douglas S, James I, Ballard C. Non-pharmacological interventions in dementia. Adv Psychiatr Treat. 2004;10:171-179
- Farlow MR, Small GW, Quarg P, Krause A. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. Dement Geriatr Cogn Disord. 2005;20:192-197. PMID: 16088144
- Erkinjuntti T, Kurz A, Small GW, et al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther. 2003 Jun;25(6):1765-1782. PMID: 12860497
- Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002 Apr;359(9314):1283-1290. PMID: 11965273
- Gauthier S, Herrmann N, Ferreri F, et al. Use of memantine to treat Alzheimer's disease. CMAJ. 2006 Aug;175(5):501-502. PMID: 16940271
- Hort J, O’Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol. 2010 Oct;17(10):1236-1248. doi: 10.111/j.1468-1331.2010.03040.x. PMID: 20831773
- Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2003(1)
- Ihl R, Bachinskaya N, Korczyn A, et al. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry. 2010 Nov;26(11):1186-1194. doi: 10.1002/gps.2662. PMID: 21140383
- Ihl R, Frolich L, Winblad B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. World J Biol Psychiatry. 2011 Feb;12(1):002-32. PMID: 21288069
- Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2000;4:CD002854. doi: 10.1002/14651858.CD002854. PMID: 11034775
- Lanctot KL, Hermann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ. 2003 Sep;169(6):557-564. PMID: 12975222
- Kasper S, Schubert H. Ginkgo biloba extract EGb 761 in the treatment of dementia: evidence of efficacy and tolerability. Fortschr Neurol Psychiatr. 2009 Sep;77(9):494-506. doi: 10.1055/s-0028-1109504. Accessed 04 Apr 2011. PMID: 19621278
- Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May;56(9):1143-1153. PMID: 11342678
- Lippa CF, Duda JE, Grossman H, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007 Mar;68(11):812-819. PMID: 17353469
- Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med. 1999 Nov;341(22):1670-1679. PMID: 10572156
- Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May;56(9):1133-1142. PMID: 11342677
- Roman GC. Rivastigmine for subcortical vascular dementia. Expert Rev Neurother. 2005 May;5(3):309-313. PMID: 15938663
- Wei ZH, He QB, Wang H, et al. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease [abstract]. J Neural Transm. 2007;114(5):629-634. http://www.ncbi.nlm.nih.gov. Accessed 15 Mar 2011. PMID: 17318304
- Plosker GL, Gauthier S. Cerebrolysin: A review of its use in dementia [abstract]. Drugs & Aging. 2009 Nov;26(11):893-915. doi: 10.2165/11203320-000000000-00000. Accessed 15 Mar 2011. PMID: 19848437
- Ubhi K, Rockenstein E, Doppler E, et al. Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin. Acta Neuropathol. 2009 Jun;117(6):699-712. PMID: 19252918
- Weinmann S, Roll S, Schwarzbach C, et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010 Mar;10(14):001-12. http://www.biomedcentral.com. Accessed 04 Apr 2011. PMID: 20236541
- MedWormhttp://www.medworm.com/rss/index.php/Neurology/25/http://www.medworm.com/rss/medicalfeeds/specialities/Neurology.xml
- MedWorm http://www.medworm.com/rss/index.php/Psychiatry/172/ www.medworm.com/rss/medicalfeeds/specialities/Psychiatry-News.xml
- Kuljis R. Alzheimer disease. eMedicine. http://emedicine.medscape.com. 2007.
- Ministry of Health Singapore. Clinical practice guidelines: dementia. MOH (Singapore). http://www.moh.gov.sg. 2007. Accessed 15 Mar 2011.
- Academy of Medicine of Malaysia, Ministry of Health of Malaysia. Clinical practice guidelines for management of dementia. Academy of Medicine of Malaysia. http://www.acadmed.org.my. Jun 2003.
- National Collaborating Centre for Mental Health. Dementia: supporting people with dementia and their carers in health and social care. National Clinical Practice guideline No. 42. NICE. http://www.nice.org.uk. 2007. Accessed 15 Mar 2011.
- National Institute for Health and Care Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease. Review of NICE technology appraisal guidance 111. NICE. http://www.nice.org.uk. Sep 2007.
- National Collaborating Centre for Mental Health. Dementia: supporting people with dementia and their carers in health and social care. National Clinical Practice guideline No. 42. NICE. http://www.nice.org.uk. 2011. Accessed 05 Apr 2011.
- American Psychiatric Association. Guideline watch: practice guidelines for the treatment of patients with Alzheimer’s disease and other dementias of late life. Psychiatryonline. www.psychiatryonline.org. Apr 2006
- Fisher Center for Alzheimer’s Research Foundation. New concerns raised about vitamin E and Alzheimer’s. http://www.alzinfo.org. 29 Nov 2004.
- Scottish Intercollegiate Guidelines Network. Management of patients with dementia: national clinical guideline. SIGN. http://www.sign.ac.uk. Feb 2006.
- American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias [2nd ed]. Psychiatryonline. http://www.psychiatryonline.com. Oct 2007. Accessed 15 Mar 2011.
- Rabins P, Rovner B, Rummans T, et al. Guideline watch (October 2014): practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Psychiatryonline. http://psychiatryonline.org. Oct 2014. Accessed 18 Aug 2015.
- The Hong Kong Geriatrics Society. Treatment guideline and practical tips in using cholinesterase inhibitors and NMDA receptor antagonist. In: Wai AYT. Practical manual of neurocognitive disorders in older adults; 2014 Jun:162-167.
- Prince M, Wilmo A, Guerchet M, et al. World Alzheimer Report 2015 - the global Impact of dementia: an analysis of prevalence, incidence, cost and trends. . Alzheimer’s Disease International. http://www.alz.co.uk. 2015.
- Keene CD, Montine TJ, Kuller LH. Epidemiology, pathology and pathogenesis of Alzheimer disease. UpToDate. https://www.uptodate.com. Jan 2018. Accessed 26 Apr 2017.
- World Health Organization. Risk reduction of cognitive decline and dementia: WHO guidelines. WHO. http://www.who.int. 2019.
- Farlow MR. Clinical features and diagnosis of dementia with Lewy bodies. UpToDate. http://www.uptodate.com. Aug 2017.
- Larson EB. Evaluation of cognitive impairment and dementia. UpToDate. http://www.uptodate.com. May 2019.
- Press D, Alexander M. Treatment of dementia. UpToDate. http://www.uptodate.com. Jan 2018.
- Press D, Alexander M. Management of neuropsychiatric symptoms of dementia. UpToDate. http://www.uptodate.com. Nov 2018. Accessed 10 Jun 2019.
- Wolk DA, Dickerson BC. Clinical features and diagnosis of Alzheimer disease. UpToDate. http://www.uptodate.com. Nov 2018.
- Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Jan;90(3):126-135. doi: 10.1212/WNL.0000000000004826. PMID: 29282327
- Academy of Medicine Malaysia, Ministry of Health Malaysia. Management of dementia (2nd edition). http://www.acadmed.org.my. 2009. Accessed 10 Jun 2019.
- Cognitive Decline Partnership Centre. Clinical practice guidelines and principles of care for people with dementia. Australian Clinical Practice Guidelines. http://www.clinicalguidelines.gov.au. 2016.
- Epperly T, Dunay MA, Boice JL. Alzheimer disease: Pharmacologic and nonpharmacologic therapies for cognitive and functional symptoms. Am Fam Physician. 2017 Jun;95(12):771-778. PMID: 28671413
- Farlow MR, Small GW, Quarg P, et al. Efficacy of rivastigmine in alzheimer’s disease patients with rapid disease progression: Results of a meta-analysis. Dement Geriatr Cogn Disord. 2005;20(2-3):192-197. doi: 10.1159/000087301. PMID: 16088144
- Larson EB. Risk factors for cognitive decline and dementia. UpToDate. http://www.uptodate.com. Dec 2017. Accessed 10 Jun 2019.
- Lorentz WJ, Scanlan JM, Borson S. Brief screening tests for dementia. Can J Psychiatry. 2002 Oct;47(8):723-733. doi: 10.1177/070674370204700803. PMID: 12420650
- Ministry of Health Singapore. Dementia: MOH clinical practice guidelines 1/2013. http://www. moh.gov.sg. Apr 2013.
- National Institute for Health and Care Excellence (NICE). Donezepil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease NICE technology appraisal guidance 217. NICE. http://www.nice.org.uk. Mar 2011.
- Peterson R, Graff-Radford J. Alzheimer disease and other dementias. In: Daroff RB, Jankovic J, Mazziotta JC, et al. Bradley's Neurology in Clinical Practice. 7th ed. Philadelphia, Pennsylvania, USA: Saunders, Elsevier; 2016. http://dx.doi.org/10.1016/B978-0-323-28783-8.00095-8. :1380-1421.
- Press D, Alexander M. Cholinesterase inhibitors in the treatment of dementia. UpToDate. http://www.uptodate.com. Mar 2018.
- Qui C, Kivipelto M, von Strauss E. Epidemiology of alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111-128. PMID: 19585947
- Reese TR, Thiel DJ, Cocker KE. Behavioral disorders in dementia: appropriate nondrug interventions and antipsychotic use. Am Fam Physician. 2016 Aug;94(4):276-282. PMID: 27548592
- Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016 May;173(5):543-546. doi: 10.1176/appi.ajp.2015.173501. PMID: 27133416
- Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012 Sep;19(9):1159-1179. doi: 10.1111/j.1468-1331.2012.03784.x. PMID: 22891773
- Frederiksen KS, Cooper C, Frisoni GB, et al. A European Academy of Neurology guideline on medical management issues in dementia. Eur J Neurol. 2020 Jul;0:1-16. doi: 10.1111/ene.14412.
- Ismail Z, Black SE, Camicioli R, et al. Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. Alzheimer’s Dement. 2020;16:1182-1195. doi: 10.1002/alz.12105. Accessed 17 Nov 2020
- Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020 Aug;396(10248):10248. doi: 10.1016/S0140-6736(20)30367-6. PMID: 32738937
- Smith E, Wright CB. Etiology, clinical manifestations, and diagnosis of vascular dementia. UpToDate. https://www.uptodate.com. 17 Nov 2020.
- Winslow BT, Onysko MK, Stob CM , et al. Treatment of Alzheimer disease. Am Fam Physician. 2011 Jun;83(12):1403-1412. PMID: 21671540